Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Amphotericin B | Case report

Gut-derived fungemia due to Kodamaea ohmeri combined with invasive pulmonary aspergillosis: a case report

Authors: Zi-Mu Li, Yu-Kun Kuang, Yi-Fan Zheng, Pei-Hang Xu, Ji-Yu Wang, Run-Jing Gan, Hui-Xia Li, Li-Hong Bai, Can-Mao Xie, Ke-Jing Tang

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Kodamaea ohmeri is a rare pathogen with high mortality and is found among blood samples in a considerable proportion; however, gastrointestinal infection of K. ohmeri is extremely rare. Invasive pulmonary aspergillosis is also an uncommon fungal; these two fungal infections reported concomitantly are unprecedented.

Case presentation

We described a case of a 37-year-old male who got infected with K. ohmeri and invasive pulmonary aspergillosis. We used the mass spectrometry and histopathology to identify these two fungal infections separately. For the treatment of K. ohmeri, we chose caspofungin. As for invasive pulmonary aspergillosis, we used voriconazole, amphotericin B, and then surgery. The patient was treated successfully through the collaboration of multiple disciplines.

Conclusions

We speculate that the destruction of the intestinal mucosa barrier can make the intestine one of the ways for certain fungi to infect the human body.
Literature
1.
Chakrabarti A, Rudramurthy SM, Kale P, Hariprasath P, Dhaliwal M, Singhi S, et al. Epidemiological study of a large cluster of fungaemia cases due to Kodamaea ohmeri in an Indian tertiary care centre. Clin Microbiol Infect. 2014;20(2):O83-89.PubMedCrossRef
2.
Bergman MM, Gagnon D, Doern GV. Pichia ohmeri fungemia. Diagn Microbiol Infect Dis. 1998;30(3):229–31.PubMedCrossRef
3.
4.
Ioannou P, Papakitsou I. Kodamaea ohmeri infections in humans: a systematic review. Mycoses. 2020;63(7):636–43.PubMedCrossRef
5.
Souza JAM, Gurgel I, Malacco N, Martins FRB, Queiroz-Junior CM, Teixeira MM, et al. Pre-exposure with extracellular vesicles from aspergillus fumigatus attenuates inflammatory response and enhances fungal clearance in a murine model pulmonary aspergillosis. Front Cell Infect Microbiol. 2022;12: 898619.PubMedPubMedCentralCrossRef
6.
Slarve M, Holznecht N, Reza H, Gilkes A, Slarve I, Olson J, et al. Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis. Vaccine. 2022;40(31):4160–8.PubMedCrossRef
7.
Jin SP, Jin ZG. A case of septicemia caused by Kodamaea ohmeri. Chin J Clin Lab Sci. 1994;3:167.
8.
Choy BY, Wong SS, Chan TM, Lai KN. Pichia ohmeri peritonitis in a patient on CAPD: response to treatment with amphotericin. Perit Dial Int. 2000;20(1):91.PubMedCrossRef
9.
Matute AJ, Visser MR, Lipovsky M, Schuitemaker FJ, Hoepelman AI. A case of disseminated infection with Pichia ohmeri. Eur J Clin Microbiol Infect Dis. 2000;19(12):971–3.PubMedCrossRef
10.
Hitomi S, Kumao T, Onizawa K, Miyajima Y, Wakatsuki T. A case of central-venous-catheter-associated infection caused by Pichia ohmeri. J Hosp Infect. 2002;51(1):75–7.PubMedCrossRef
11.
Huang ZG. Kodamaea ohmeri was detected in the blood of one patient. Chin J Lab Med. 2002;4:225.
12.
Joao I, Duarte J, Cotrim C, Rodrigues A, Martins C, Fazendas P, et al. Native valve endocarditis due to Pichia ohmeri. Heart Vessels. 2002;16(6):260–3.PubMedCrossRef
13.
Liu DM, An YL, Su F. A case report of hematuria caused by Kodamaea ohmeri. Chin J Lab Med. 2002;1:31.
14.
Puerto JL, Garcia-Martos P, Saldarreaga A, Ruiz-Aragon J, Garcia-Agudo R, Aoufi S. First report of urinary tract infection due to Pichia ohmeri. Eur J Clin Microbiol Infect Dis. 2002;21(8):630–1.PubMedCrossRef
15.
Reina JP, Larone DH, Sabetta JR, Krieger KK, Hartman BJ. Pichia ohmeri prosthetic valve endocarditis and review of the literature. Scand J Infect Dis. 2002;34(2):140–1.PubMedCrossRef
16.
Shin DH, Park JH, Shin JH, Suh SP, Ryang DW, Kim SJ. Pichia ohmeri fungemia associated with phlebitis: successful treatment with amphotericin B. J Infect Chemother. 2003;9(1):88–9.PubMedCrossRef
17.
Han XY, Tarrand JJ, Escudero E. Infections by the yeast Kodomaea (Pichia) ohmeri: two cases and literature review. Eur J Clin Microbiol Infect Dis. 2004;23(2):127–30.PubMedCrossRef
18.
Otag F, Kuyucu N, Erturan Z, Sen S, Emekdas G, Sugita T. An outbreak of Pichia ohmeri infection in the paediatric intensive care unit: case reports and review of the literature. Mycoses. 2005;48(4):265–9.PubMedCrossRef
19.
Ostronoff F, Ostronoff M, Calixto R, Domingues MC, Souto Maior AP, Sucupira A, et al. Pichia ohmeri fungemia in a hematologic patient: an emerging human pathogen. Leuk Lymphoma. 2006;47(9):1949–51.PubMedCrossRef
20.
Taj-Aldeen SJ, Doiphode SH, Han XY. Kodamaea (Pichia) ohmeri fungaemia in a premature neonate. J Med Microbiol. 2006;55(Pt 2):237–9.PubMedCrossRef
21.
Lee JS, Shin JH, Kim MN, Jung SI, Park KH, Cho D, et al. Kodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis. J Clin Microbiol. 2007;45(3):1005–10.PubMedPubMedCentralCrossRef
22.
Mahfouz RA, Otrock ZK, Mehawej H, Farhat F. Kodamaea (Pichia) ohmeri fungaemia complicating acute myeloid leukaemia in a patient with haemochromatosis. Pathology. 2008;40(1):99–101.PubMedCrossRef
23.
De Barros JD, Do Nascimento SM, De Araujo FJ, Braz Rde F, Andrade VS, Theelen B, et al. Kodamaea (Pichia) ohmeri fungemia in a pediatric patient admitted in a public hospital. Med Mycol. 2009;47(7):775–9.PubMedCrossRef
24.
Poojary A, Sapre G. Kodamaea ohmeri infection in a neonate. Indian Pediatr. 2009;46(7):629–31.PubMed
25.
Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ. Fluconazole-resistant Kodamaea ohmeri fungemia associated with cellulitis: case report and review of the literature. Int J Infect Dis. 2009;13(6):e493-497.PubMedCrossRef
26.
Chiu CH, Wang YC, Shang ST, Chang FY. Kodamaea ohmeri fungaemia successfully treated with caspofungin. Int J Antimicrob Agents. 2010;35(1):98–9.PubMedCrossRef
27.
Menon T, Herrera M, Periasamy S, Palanivelu V, Sikhamani R, Wickes B. Oral candidiasis caused by Kodamaea ohmeri in a HIV patient in Chennai, India. Mycoses. 2010;53(5):458–9.PubMedCrossRef
28.
Shaaban H, Choo HF, Boghossian J, Perez G. Kodamaea ohmeri fungemia in an immunocompetent patient treated with micafungin: case report and review of the literature. Mycopathologia. 2010;170(4):223–8.PubMedCrossRef
29.
Shang ST, Lin JC, Ho SJ, Yang YS, Chang FY, Wang NC. The emerging life-threatening opportunistic fungal pathogen Kodamaea ohmeri: optimal treatment and literature review. J Microbiol Immunol Infect. 2010;43(3):200–6.PubMedCrossRef
30.
Yanghua Q, Weiwei W, Yang L, Jian X, Qian S. Isolation, identification, and antifungal susceptibility test for Kodamaea ohmeri: a case report on endocarditis. J Med Coll PLA. 2010;25(4):252–6.CrossRef
31.
Al-Sweih N, Khan ZU, Ahmad S, Devarajan L, Khan S, Joseph L, et al. Kodamaea ohmeri as an emerging pathogen: a case report and review of the literature. Med Mycol. 2011;49(7):766–70.PubMed
32.
Gonzalez-Avila M, Gomez-Gomez JV, Texis AP, Imbert-Palafox JL, Becerril-Flores MA, Blasco JL. Uncommon fungi isolated from diabetic patients toenails with or without visible onychomycoses. Mycopathologia. 2011;172(3):207–13.PubMedCrossRef
33.
Sundaram PS, Bijulal S, Tharakan JA, Antony M. Kodamaea ohmeri tricuspid valve endocarditis with right ventricular inflow obstruction in a neonate with structurally normal heart. Ann Pediatr Cardiol. 2011;4(1):77–80.PubMedPubMedCentralCrossRef
34.
Zhang CL, Xu DX, Wang LS, Sun RL, Li L. A case of 75-year -old woman patient with Kodamaea ohmeri fungemia treated by Caspofungin successfully. China Med Herald. 2011;8:149–51.
35.
Liu CX, Yang JH, Dong L, Mai JY, Zhang L, Zhu JH. Clinical features and homological analysis of Pichia ohmeri-caused hospital-acquired fungemia in premature infants. Nat Med J Chin. 2013;93(4):285–8.
36.
Santino I, Bono S, Borruso L, Bove M, Cialdi E, Martinelli D, et al. Kodamaea ohmeri isolate from two immunocompromised patients: first report in Italy. Mycoses. 2013;56(2):179–81.PubMedCrossRef
37.
Xiao Y, Kang M, Tang Y, Zong Z, Zhang Y, He C, et al. Kodamaea ohmeri as an emerging pathogen in mainland China: 3 case reports and literature review. Lab Med. 2013;44(SUPPL1):e1–9.CrossRef
38.
Biswal D, Sahu M, Mahajan A, Advani SH, Shah S. Kodameae ohmeri—an emerging yeast: two cases and literature review. J Clin Diagn Res. 2015;9(3):D01-03.
39.
Bokhary NA, Hussain IB. Kodamaea (Pichia) ohmeri peritonitis in a nine-year-old child in Saudi Arabia treated with caspofungin. J Taibah Uni Med Sci. 2015;10(4):492–5.
40.
Capoor MR, Gupta DK, Verma PK, Sachdeva HC. Rare yeasts causing fungemia in immunocompromised and haematology patients: case series from Delhi. Indian J Med Microbiol. 2015;33(4):576–9.PubMedCrossRef
41.
Das K, Bhattacharyya A, Chandy M, Roy MK, Goel G, Hmar L, et al. Infection control challenges of infrequent and rare fungal pathogens: lessons from disseminated Fusarium and Kodamaea ohmeri infections. Infect Control Hosp Epidemiol. 2015;36(7):866–8.PubMedCrossRef
42.
Distasi MA, Del Gaudio T, Pellegrino G, Pirronti A, Passera M, Farina C. Fungemia due to Kodamaea ohmeri: first isolating in Italy. Case report and review of literature. J Mycol Med. 2015;25(4):310–6.PubMedCrossRef
43.
Cao H, Huang B, Mao S. A case of bioprosthetic valve endocarditis due to Pichia ohmeri. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(1):72–3.PubMed
44.
Giacobino J, Montelli AC, Barretti P, Bruder-Nascimento A, Caramori JT, Barbosa L, et al. Fungal peritonitis in patients undergoing peritoneal dialysis (PD) in Brazil: molecular identification, biofilm production and antifungal susceptibility of the agents. Med Mycol. 2016;54(7):725–32.PubMedCrossRef
45.
Ma XF, Hu WB, Wang GQ, Gao WM, Wang MS, Tong GA, et al. A case of patient with pichia ohmeri fungemia associated with HLD successfully treated with caspofungin and a literature review. Anhui Med J. 2016;37:136–9.
46.
Vivas R, Beltran C, Munera MI, Trujillo M, Restrepo A, Garces C. Fungemia due to Kodamaea ohmeri in a young infant and review of the literature. Med Mycol Case Rep. 2016;13:5–8.PubMedPubMedCentralCrossRef
47.
Fernandez-Ruiz M, Guinea J, Puig-Asensio M, Zaragoza O, Almirante B, Cuenca-Estrella M, et al. Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain. Med Mycol. 2017;55(2):125–36.PubMedCrossRef
48.
Kanno Y, Wakabayashi Y, Ikeda M, Tatsuno K, Misawa Y, Sato T, et al. Catheter-related bloodstream infection caused by Kodamaea ohmeri: a case report and literature review. J Infect Chemother. 2017;23(6):410–4.PubMedCrossRef
49.
Huang JP, Tsai K-J, Lin J. Unusual fungemia in a patient with metastatic gastric cancer. J Can Res Pra. 2018;5(4):172–4.CrossRef
50.
Ni B, Gu W, Mei Y, Miao K, Zhang S, Shao Y. A rare life-threatening Kodamaea ohmeri endocarditis associated with hemophagocytic lymphohistiocytosis. Rev Esp Cardiol (Engl Ed). 2018;71(1):51–3.PubMedCrossRef
51.
Tashiro A, Nei T, Sugimoto R, Watanabe A, Hagiwara J, Takiguchi T, et al. Kodamaea ohmeri fungemia in severe burn: case study and literature review. Med Mycol Case Rep. 2018;22:21–3.PubMedPubMedCentralCrossRef
52.
Diallo K, Lefevre B, Cadelis G, Gallois JC, Gandon F, Nicolas M, et al. A case report of fungemia due to Kodamaea ohmeri. BMC Infect Dis. 2019;19(1):570.PubMedPubMedCentralCrossRef
53.
54.
Saud Al-Abbas AH, Ling JL, Muhammed J, Hussein A. Rare Kodamaea ohmeri keratitis following a trivial vegetative trauma. BMJ Case Rep. 2019;12(6):e229660.PubMedPubMedCentralCrossRef
55.
Al-Salameh N, Patel M, Kwon T. A rare case of Kodamera ohmeri endocarditis treated with isavuconazole. Chest. 2020;158(4):A473.CrossRef
56.
Yu Q, Yan J, Gao Z, Yang H, Tang Y, Yang L. Subcutaneous granuloma caused by Kodamaea ohmeri in an immunocompromised patient in China. Australas J Dermatol. 2020;61(2):e213–6.PubMedCrossRef
57.
Prabhu K, Chinniah TR. A case report of fungemia due to Kodamea ohmeri. J Infect Dis. 2021;11(1):42.
58.
Tra Bi CY, N’Guessan FK, Kouakou CA, Jacques N, Casaregola S, Dje MK. Identification of yeasts isolated from raffia wine (Raphia hookeri) produced in Cote d’Ivoire and genotyping of Saccharomyces cerevisiae strains by PCR inter-delta. World J Microbiol Biotechnol. 2016;32(8):125.PubMedCrossRef
59.
Zhou M, Yu S, Kudinha T, Xiao M, Wang H, Xu Y, et al. Identification and antifungal susceptibility profiles of Kodamaea ohmeri based on a seven-year multicenter surveillance study. Infect Drug Resist. 2019;12:1657–64.PubMedPubMedCentralCrossRef
60.
Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60.PubMedPubMedCentralCrossRef
Metadata
Title
Gut-derived fungemia due to Kodamaea ohmeri combined with invasive pulmonary aspergillosis: a case report
Authors
Zi-Mu Li
Yu-Kun Kuang
Yi-Fan Zheng
Pei-Hang Xu
Ji-Yu Wang
Run-Jing Gan
Hui-Xia Li
Li-Hong Bai
Can-Mao Xie
Ke-Jing Tang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07866-6

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue

Case report

COVID-19-associated leukoencephalopathy in the absence of severe hypoxia with subsequent improvement: a case report

Research

Determinants of therapy failure among adults on first-line antiretroviral therapy in Asmara, Eritrea: a multicenter retrospective matched case–control study

Research

Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial

Research

Respiratory virus detection in the upper respiratory tract of asymptomatic, community-dwelling older people

Research

The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study

Research

Regional opening strategies with commuter testing and containment of new SARS-CoV-2 variants in Germany
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits